


LIQUID TRACE® MRD FOR HEMATOLOGIC MALIGNANCIES

Add a new dimension to your MRD testing with cfRNA

Get more with cfRNA than cfDNA alone

Cancer patients P<0.0001



Comprehensive cfDNA + cfRNA profiling to detect minimal residual disease, monitor treatment response, and identify molecular recurrence earlier.

Residual disease may persist below the threshold of conventional assessment methods. Liquid Trace® MRD integrates cfDNA and cfRNA analysis to provide comprehensive molecular monitoring across hematologic malignancies.

WHY LIQUID TRACE® MRD?

Go Deeper and Discover More

Ultra-deep sequencing enables detection of low-frequency circulating tumor DNA and supports longitudinal disease monitoring.

Comprehensive Molecular Profiling

- Somatic mutation profiling
- Gene fusions and translocations
- Copy number alterations
- Gene expression profiling
- B- and T-cell clonality assessment
- HLA genotyping
- Viral RNA detection of HTLV-1, TTV and EBV
- AI-supported molecular classification

Sensitive Longitudinal Monitoring

Track molecular response and detect residual disease over time using plasma-based testing.

Liquid Trace Hematology Tumor Agnostic Testing

Sensitivity on hotspots

0.001%

Sensitivity across Liquid Trace

>0.1%

Read Depth

25,000 – 30,000X

**Increase Sensitivity by Ordering
Tumor Informed Testing**

CLINICAL APPLICATIONS

Monitor Residual Disease

Assess treatment response and detect persistent disease following therapy.

Detect Molecular Relapse

Identify molecular recurrence earlier and monitor disease progression.




Evaluate Response to Advanced Therapies

Monitor disease dynamics during targeted therapies, immunotherapies, and cellular therapies.


Follow Clonal Evolution

Monitor changes in mutational profiles and emerging disease subclones.

Unique Testing by Combining Mutation with Clonality



Get Reliable Results with Clonotype Agnostic Testing
Increase Sensitivity by Ordering Clonotype Informed Testing



REPORTING INCLUDES

- MRD status
- Mutation tracking and quantitative assessment
- B- and T-cell clonality analysis
- Gene fusion and chromosomal abnormality assessment
- Longitudinal molecular monitoring
- Clinically actionable biomarkers

SPECIMEN REQUIREMENTS

One 10 mL EDTA blood tube or one 7mL CSF collected in clear CSF tube



To Order Kits Scan the QR code or Email:
clientservices@genomictestingcooperative.com

